ClinicalTrials.gov record
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Acute Symptoms of Chronic Bronchitis

ClinicalTrials.gov ID: NCT00644449

Public ClinicalTrials.gov record NCT00644449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 30, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis (AECB)

Study identification

NCT ID
NCT00644449
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
551 participants

Conditions and interventions

Interventions

  • azithromycin SR (Zithromax; compound: CP-62,993) Drug
  • levofloxacin Drug
  • placebo Other

Drug · Other

Eligibility (public fields only)

Age range
35 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2002
Primary completion
Not listed
Completion
Feb 29, 2004
Last update posted
May 15, 2011

2003 – 2004

United States locations

U.S. sites
29
U.S. states
14
U.S. cities
24
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35215
Pfizer Investigational Site Birmingham Alabama 35233
Pfizer Investigational Site Columbiana Alabama 35051
Pfizer Investigational Site Tallassee Alabama 36078
Pfizer Investigational Site Mesa Arizona 85201
Pfizer Investigational Site Phoenix Arizona 85014
Pfizer Investigational Site Tempe Arizona 85282
Pfizer Investigational Site Daytona Beach Florida 32114
Pfizer Investigational Site Merritt Island Florida 32953
Pfizer Investigational Site Austell Georgia 30106
Pfizer Investigational Site Evansville Indiana 47712
Pfizer Investigational Site Madisonville Kentucky 42431
Pfizer Investigational Site New Orleans Louisiana 70115
Pfizer Investigational Site Kalamazoo Michigan 49009
Pfizer Investigational Site Royal Oak Michigan 48073
Pfizer Investigational Site Olive Branch Mississippi 38654
Pfizer Investigational Site Elkhorn Nebraska 68022
Pfizer Investigational Site Omaha Nebraska 68105
Pfizer Investigational Site Omaha Nebraska 68144
Pfizer Investigational Site Columbus Ohio 43214
Pfizer Investigational Site Columbus Ohio 43215
Pfizer Investigational Site Columbus Ohio 43222
Pfizer Investigational Site Allentown Pennsylvania 18102
Pfizer Investigational Site Harrisburg Pennsylvania 17011
Pfizer Investigational Site Harrisburg Pennsylvania 17110
Pfizer Investigational Site Morrisville Pennsylvania 19067
Pfizer Investigational Site Willow Grove Pennsylvania 19090
Pfizer Investigational Site Milan Tennessee 38358
Pfizer Investigational Site San Antonio Texas 78224

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00644449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 15, 2011 · Synced Apr 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00644449 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →